Pancreatic cancer has the highest mortality rate among major cancers and is currently the third leading cause of cancer-related deaths in the United States, following lung and colon cancer. It is projected to become the second leading cause by 2030. (Source: Hirshberg Foundation). Pancreatic cancer may be treated with surgery if caught early, as well as with chemotherapy, radiation, or targeted therapies, but treatments that consistently improve survival are still limited. In the U.S., only about 10% of patients live for at least 5 years after being diagnosed with pancreatic cancer. Gemcitabine-based therapies, especially in combination with Abraxane, are the most widely used pancreatic cancer treatment category.
The stock we are bringing to your attention today is Actuate Therapeutics Inc. (ACTU), which is developing a drug for metastatic pancreatic cancer.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.